TRANSCENTA Holding Limited (TRANSCENTA-B) will convene its 2026 Annual General Meeting on 30 June 2026 at 10:00 a.m. at B6-501, 218 Xinghu Street, Biobay, Suzhou, China.

Key resolutions to be submitted for shareholder voting are as follows:

1. 2025 Financial Statements • Adoption of the audited consolidated financial statements and accompanying directors’ and auditor’s reports for the year ended 31 December 2025.

2. Board Composition • Re-election of Dr. Xueming Qian as Executive Director. • Re-election of Ms. Helen Wei Chen as Independent Non-Executive Director. • Authorisation for the board to fix directors’ remuneration. • Appointment of Dr. Hansen Xu as Non-Executive Director. • Appointment of Dr. Jun Bao as Independent Non-Executive Director.

3. Auditor • Re-appointment of Ernst & Young as external auditor and authorisation for the board to set its remuneration.

4. Share Mandates • General mandate allowing the board to repurchase shares representing up to 10% of the company’s issued share capital (excluding treasury shares) as of the approval date. • General mandate permitting issuance, allotment and dealing of additional shares— including any sale or transfer of treasury shares—up to 20% of issued share capital (excluding treasury shares). • Extension of the issuance mandate by the aggregate number of shares repurchased under the 10% buy-back mandate.

Proxy forms and related authorisations must be lodged with Tricor Investor Services Limited no later than 10:00 a.m. on 28 June 2026 (Hong Kong time) to be valid for the meeting.